Last reviewed · How we verify
mixed salts amphetamine
Mixed salts amphetamine increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing attention and reducing impulsivity.
Mixed salts amphetamine increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing attention and reducing impulsivity. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | mixed salts amphetamine |
|---|---|
| Also known as | Adderall |
| Sponsor | Rush University Medical Center |
| Drug class | Sympathomimetic amine; CNS stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Amphetamine is a sympathomimetic amine that acts as a potent releaser of catecholamines (dopamine and norepinephrine) from presynaptic neurons and inhibits their reuptake via monoamine transporters. This results in increased synaptic concentrations of these neurotransmitters, which enhances alertness, focus, and executive function while reducing hyperactivity and impulsive behavior in patients with attention deficit disorders.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Tachycardia
- Elevated blood pressure
- Tremor
Key clinical trials
- The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine (PHASE4)
- Adaptive Response to Intervention (RTI) for Students With ADHD (PHASE4)
- WAKIX® (Pitolisant) Pregnancy Registry
- Biomarkers of ADHD Treatment Response (PHASE1)
- Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial (PHASE3)
- Adderall XR and Cognitive Impairment in MS (PHASE2, PHASE3)
- Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment (NA)
- Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mixed salts amphetamine CI brief — competitive landscape report
- mixed salts amphetamine updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI